HC Wainwright Issues Negative Outlook for Evotec Earnings

Evotec AG (NASDAQ:EVO) – Investment analysts at HC Wainwright lowered their Q3 2026 EPS estimates for Evotec in a note issued to investors on Wednesday, July 15th. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($0.04) per share for the quarter, down from their prior forecast of ($0.01). HC Wainwright currently has a “Buy” rating and a $4.00 target price on the stock. The consensus estimate for Evotec’s current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Evotec’s Q4 2026 earnings at ($0.02) EPS, FY2026 earnings at ($0.31) EPS and FY2027 earnings at $0.07 EPS.

Evotec (NASDAQ:EVO) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $0.05 EPS for the quarter. The business had revenue of $297.02 million for the quarter. Evotec had a negative return on equity of 24.93% and a negative net margin of 26.20%.

A number of other equities analysts have also recently commented on the company. Weiss Ratings upgraded Evotec from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, April 24th. Berenberg Bank cut shares of Evotec from a “buy” rating to a “hold” rating in a research report on Thursday. TD Cowen lowered shares of Evotec from a “buy” rating to a “hold” rating and set a $2.00 price objective for the company. in a research note on Wednesday. Finally, Wall Street Zen downgraded shares of Evotec from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $3.00.

Evotec Trading Down 2.0%

NASDAQ:EVO opened at $1.97 on Friday. The stock’s fifty day moving average is $2.77 and its two-hundred day moving average is $3.02. Evotec has a 52 week low of $1.96 and a 52 week high of $4.41. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.60 and a current ratio of 1.68.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. ABC Arbitrage SA boosted its stake in Evotec by 319.7% in the fourth quarter. ABC Arbitrage SA now owns 554,287 shares of the company’s stock valued at $1,707,000 after acquiring an additional 422,230 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Evotec by 25.7% in the 4th quarter. Wellington Management Group LLP now owns 1,797,444 shares of the company’s stock valued at $5,536,000 after purchasing an additional 367,545 shares during the last quarter. Optiver Holding B.V. lifted its holdings in shares of Evotec by 598.4% in the 1st quarter. Optiver Holding B.V. now owns 283,576 shares of the company’s stock valued at $709,000 after purchasing an additional 242,973 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Evotec in the 4th quarter valued at about $565,000. Finally, Millennium Management LLC acquired a new stake in shares of Evotec in the 4th quarter valued at about $317,000. Institutional investors and hedge funds own 5.81% of the company’s stock.

Evotec News Summary

Here are the key news stories impacting Evotec this week:

• Positive Sentiment: HC Wainwright still rates Evotec Buy and maintained a $4.00 price target, suggesting upside from current levels despite near-term earnings pressure.
• Neutral Sentiment: The company’s Q2 2026 earnings call highlighted ongoing revenue declines and strategic changes, which gives investors more context on management’s turnaround efforts. Article Title
• Negative Sentiment: HC Wainwright cut its earnings forecasts across several periods, including Q3 2026, Q4 2026, FY2026, and FY2027, signaling weaker expected profitability than before.
• Negative Sentiment: Berenberg Bank downgraded Evotec AG (NASDAQ: EVO) from buy to hold, a cautious call that may have added to selling pressure.
• Negative Sentiment: The revised estimates still imply losses in 2026 and only a return to modest profit in 2027, which may disappoint investors looking for a faster earnings rebound.

Evotec Company Profile

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.